MENUNews Archive
Date: 01/17/2021
Research at the U-M Rogel Cancer Center finds that tumors in the liver siphon off critical immune cells, rendering immunotherapy ineffective. But coupling immunotherapy with radiotherapy to the liver in mice restored the immune cell function and led to better outcomes.
Date: 12/19/2020
Two proteins, ACE2 and TMPRSS2, help the coronavirus gain entry and replicate within cells. TMPRSS2 is well-known to Arul Chinnaiyan, M.D., Ph.D.
Date: 12/19/2020
A new study finds that appealing to people’s concerns for their loved ones could overcome this resistance. And it may have implications for encouraging people to get the new vaccine.
Date: 12/19/2020
Income level, employment, housing location, medical insurance, education, tobacco and alcohol use, diet and obesity, access to medical care. These are some of the factors causing worse COVID-19 outcomes in people who are Black.
Date: 12/18/2020
Eight University of Michigan faculty members -- including three members of the U-M Rogel Cancer Center - have been elected 2020 fellows of the American Association for the Advancement of Science.
Date: 12/18/2020
A combination approach to treating a prevalent glioma subtype -- including metabolic reprogramming, radiation, chemotherapy and immunotherapy -- led to a complete regression of tumors in 60% of study mice.
Date: 12/15/2020
Despite the increase in use of e-cigarettes among adolescents, cigarette and smokeless tobacco prevalence declined more rapidly between 2012 and 2019 than in previous periods.
Date: 12/10/2020
Physicians did not recognize side effects from radiation therapy in more than half of breast cancer patients who reported a significant symptom, a new study finds.
Date: 10/30/2020
A new study combined single-cell RNA sequencing with two other investigative techniques to create what is believed to be the most robust and detailed portrait to date of the network of interactions that suppress the body’s immune response in and around pancreatic tumors.
Date: 10/28/2020
The U-M-led development and validation of a staging system for non-metastatic prostate cancer could help doctors and patients assess treatment options, as well as improve clinical trials.